Literature DB >> 23695963

Pathologic and gene expression features of metastatic melanomas to the brain.

Ronald Hamilton1, Michal Krauze, Marjorie Romkes, Bernard Omolo, Panagiotis Konstantinopoulos, Todd Reinhart, Malgorzata Harasymczuk, YangYang Wang, Yan Lin, Soldano Ferrone, Theresa Whiteside, Stephanie Bortoluzzi, Jonette Werley, Tomoko Nukui, Beth Fallert-Junecko, Douglas Kondziolka, Joseph Ibrahim, Dorothea Becker, John Kirkwood, Stergios Moschos.   

Abstract

BACKGROUND: The prognosis of metastatic melanomas to the brain (MBM) is variable with prolonged survival in a subset. It is unclear whether MBM differ from extracranial metastases (EcM) and primary melanomas (PrM).
METHODS: To study the biology of MBM, histopathologic analysis of tumor blocks from patients' craniotomy samples and whole-genome expression profiling (WGEP) with confirmatory immunohistochemistry were performed.
RESULTS: High mononuclear infiltrate and low intratumoral hemorrhage were associated with prolonged overall survival (OS). Pathway analysis of WGEP data from 29 such craniotomy tumor blocks demonstrated that several immune-related BioCarta gene sets were associated with prolonged OS. WGEP analysis of MBM in comparison with same-patient EcM and PrM showed that MBM and EcM were similar, but both differ significantly from PrM. Immunohistochemical analysis revealed that peritumoral CD3⁺ and CD8⁺ cells were associated with prolonged OS.
CONCLUSIONS: MBMs are more similar to EcM compared with PrM. Immune infiltrate is a favorable prognostic factor for MBM.
© 2013 American Cancer Society.

Entities:  

Keywords:  brain metastases; craniotomy immune infiltrate; gene expression profiling; melanoma

Mesh:

Year:  2013        PMID: 23695963      PMCID: PMC3901051          DOI: 10.1002/cncr.28029

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

1.  MALIGNANT MELANOMA OF UNKNOWN PRIMARY ORIGIN.

Authors:  T DASGUPTA; L BOWDEN; J W BERG
Journal:  Surg Gynecol Obstet       Date:  1963-09

2.  NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Authors:  John A Jakob; Roland L Bassett; Chaan S Ng; Jonathan L Curry; Richard W Joseph; Gladys C Alvarado; Michelle L Rohlfs; Jessie Richard; Jeffrey E Gershenwald; Kevin B Kim; Alexander J Lazar; Patrick Hwu; Michael A Davies
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

3.  The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.

Authors:  Adam I Riker; Steven A Enkemann; Oystein Fodstad; Suhu Liu; Suping Ren; Christopher Morris; Yaguang Xi; Paul Howell; Brandon Metge; Rajeev S Samant; Lalita A Shevde; Wenbin Li; Steven Eschrich; Adil Daud; Jingfang Ju; Jaime Matta
Journal:  BMC Med Genomics       Date:  2008-04-28       Impact factor: 3.063

4.  Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis.

Authors:  Eun Sung Park; Sun Jin Kim; Seung Wook Kim; Se-Lyun Yoon; Sun-Hee Leem; Sang-Bae Kim; Soo Mi Kim; Yun-Yong Park; Jae-Ho Cheong; Hyun Goo Woo; Gordon B Mills; Isaiah J Fidler; Ju-Seog Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

5.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

Authors:  Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascierto; Paul B Chapman; Igor Puzanov; Axel Hauschild; Caroline Robert; Alain Algazi; Laurent Mortier; Hussein Tawbi; Tabea Wilhelm; Lisa Zimmer; Julie Switzky; Suzanne Swann; Anne-Marie Martin; Mary Guckert; Vicki Goodman; Michael Streit; John M Kirkwood; Dirk Schadendorf
Journal:  Lancet Oncol       Date:  2012-10-08       Impact factor: 41.316

6.  Keratin expression and its significance in five cultured melanoma cell lines derived from primary, recurrent and metastasized melanomas.

Authors:  Y Katagata; S Kondo
Journal:  FEBS Lett       Date:  1997-04-21       Impact factor: 4.124

7.  Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.

Authors:  Kelly G Paulson; Jayasri G Iyer; Andrew R Tegeder; Renee Thibodeau; Janell Schelter; Shinichi Koba; David Schrama; William T Simonson; Bianca D Lemos; David R Byrd; David M Koelle; Denise A Galloway; J Helen Leonard; Margaret M Madeleine; Zsolt B Argenyi; Mary L Disis; Juergen C Becker; Michele A Cleary; Paul Nghiem
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

8.  Down-regulation of CD3zeta is a breast cancer biomarker associated with immune suppression.

Authors:  Bin Yu; Wei Zhang
Journal:  Cell Biol Int       Date:  2011-02       Impact factor: 3.612

9.  Prognostic factors for survival in melanoma patients with brain metastases.

Authors:  Michael A Davies; Ping Liu; Susan McIntyre; Kevin B Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Agop Bedikian
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

10.  Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

Authors:  Heike Niessner; Andrea Forschner; Bernhard Klumpp; Jürgen B Honegger; Maria Witte; Antje Bornemann; Reinhard Dummer; Annemarie Adam; Jürgen Bauer; Ghazaleh Tabatabai; Keith Flaherty; Tobias Sinnberg; Daniela Beck; Ulrike Leiter; Cornelia Mauch; Alexander Roesch; Benjamin Weide; Thomas Eigentler; Dirk Schadendorf; Claus Garbe; Dagmar Kulms; Leticia Quintanilla-Martinez; Friedegund Meier
Journal:  Cancer Med       Date:  2013-02-03       Impact factor: 4.452

View more
  19 in total

1.  Use of Susceptibility-Weighted Imaging (SWI) in the Detection of Brain Hemorrhagic Metastases from Breast Cancer and Melanoma.

Authors:  Ana Marija Franceschi; Stergios J Moschos; Carey K Anders; Samuel Glaubiger; Frances A Collichio; Carrie B Lee; Mauricio Castillo; Yueh Z Lee
Journal:  J Comput Assist Tomogr       Date:  2016 Sep-Oct       Impact factor: 1.826

Review 2.  Current approaches to the treatment of metastatic brain tumours.

Authors:  Taofeek K Owonikoko; Jack Arbiser; Amelia Zelnak; Hui-Kuo G Shu; Hyunsuk Shim; Adam M Robin; Steven N Kalkanis; Timothy G Whitsett; Bodour Salhia; Nhan L Tran; Timothy Ryken; Michael K Moore; Kathleen M Egan; Jeffrey J Olson
Journal:  Nat Rev Clin Oncol       Date:  2014-02-25       Impact factor: 66.675

3.  Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab.

Authors:  C Frenard; L Peuvrel; M Saint Jean; A Brocard; A C Knol; J M Nguyen; A Khammari; G Quereux; B Dreno
Journal:  J Neurooncol       Date:  2015-10-28       Impact factor: 4.130

4.  PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Authors:  Lucia B Jilaveanu; Fabio Parisi; Meaghan L Barr; Christopher R Zito; William Cruz-Munoz; Robert S Kerbel; David L Rimm; Marcus W Bosenberg; Ruth Halaban; Yuval Kluger; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

5.  Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.

Authors:  Harriet M Kluger; Christopher R Zito; Meaghan L Barr; Marina K Baine; Veronica L S Chiang; Mario Sznol; David L Rimm; Lieping Chen; Lucia B Jilaveanu
Journal:  Clin Cancer Res       Date:  2015-03-18       Impact factor: 12.531

6.  Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era.

Authors:  Daniel A Wattson; Ryan J Sullivan; Andrzej Niemierko; Ryan M Merritt; Donald P Lawrence; Kevin S Oh; Keith T Flaherty; Helen A Shih
Journal:  J Neurooncol       Date:  2015-04-12       Impact factor: 4.130

7.  Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.

Authors:  Grant M Fischer; Ali Jalali; David A Kircher; Won-Chul Lee; Jennifer L McQuade; Lauren E Haydu; Aron Y Joon; Alexandre Reuben; Mariana P de Macedo; Fernando C L Carapeto; Chendong Yang; Anuj Srivastava; Chandrashekar R Ambati; Arun Sreekumar; Courtney W Hudgens; Barbara Knighton; Wanleng Deng; Sherise D Ferguson; Hussein A Tawbi; Isabella C Glitza; Jeffrey E Gershenwald; Y N Vashisht Gopal; Patrick Hwu; Jason T Huse; Jennifer A Wargo; P Andrew Futreal; Nagireddy Putluri; Alexander J Lazar; Ralph J DeBerardinis; Joseph R Marszalek; Jianjun Zhang; Sheri L Holmen; Michael T Tetzlaff; Michael A Davies
Journal:  Cancer Discov       Date:  2019-02-20       Impact factor: 39.397

8.  A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.

Authors:  James J Harding; Federica Catalanotti; Rodrigo R Munhoz; Donavan T Cheng; Amin Yaqubie; Nicole Kelly; Gregory C McDermott; Romona Kersellius; Taha Merghoub; Mario E Lacouture; Richard D Carvajal; Katherine S Panageas; Michael F Berger; Neal Rosen; David B Solit; Paul B Chapman
Journal:  Oncologist       Date:  2015-05-08

9.  Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.

Authors:  Guo Chen; Nitin Chakravarti; Kimberly Aardalen; Alexander J Lazar; Michael T Tetzlaff; Bradley Wubbenhorst; Sang-Bae Kim; Scott Kopetz; Alicia A Ledoux; Y N Vashisht Gopal; Cristiano Goncalves Pereira; Wanleng Deng; Ju-Seog Lee; Katherine L Nathanson; Kenneth D Aldape; Victor G Prieto; Darrin Stuart; Michael A Davies
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

10.  Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue.

Authors:  Marta Marquié; Marc D Normandin; Charles R Vanderburg; Isabel M Costantino; Elizabeth A Bien; Lisa G Rycyna; William E Klunk; Chester A Mathis; Milos D Ikonomovic; Manik L Debnath; Neil Vasdev; Bradford C Dickerson; Stephen N Gomperts; John H Growdon; Keith A Johnson; Matthew P Frosch; Bradley T Hyman; Teresa Gómez-Isla
Journal:  Ann Neurol       Date:  2015-09-25       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.